Summary
Unable to verify alignment with FDA-approved prescribing information because no FDA label text or section citations were provided; the extracted claims are marked 'absent from the label' based on missing label content.
Category Scores
Accurate Statements
Unsupported Statements
Pricing for Skyrizi (risankizumab) in Canada can vary depending on whether the drug is billed through public drug plans, private insurance, or patient-paid programs.
Not supported by the supplied FDA label content (no label text provided).
Pricing for Skyrizi in Canada can vary depending on whether costs are tied to the list price, negotiated plan pricing, or administered/institutional billing.
Not supported by the supplied FDA label content (no label text provided).
A single comparable “Canada price” for Skyrizi is usually not published for every patient.
Not supported by the supplied FDA label content (no label text provided).
Most Canadian patients do not pay the full branded drug price directly.
Not supported by the supplied FDA label content (no label text provided).
A Canadian patient’s total cost for Skyrizi depends on whether the medicine is covered by an insurer or a provincial program.
Not supported by the supplied FDA label content (no label text provided).
A Canadian patient’s total cost for Skyrizi depends on the billing model used by the clinic/hospital/infusion setting that administers the injection.
Not supported by the supplied FDA label content (no label text provided).
A Canadian patient’s total cost for Skyrizi depends on whether the patient qualifies for manufacturer assistance or third-party support programs.
Not supported by the supplied FDA label content (no label text provided).
Coverage of Skyrizi in Canada depends on the province’s formulary decisions and criteria.
Not supported by the supplied FDA label content (no label text provided).
Coverage of Skyrizi in Canada can depend on diagnosis and step-therapy requirements.
Not supported by the supplied FDA label content (no label text provided).
Even when Skyrizi is listed on a provincial formulary, patient copays can differ substantially by plan.
Not supported by the supplied FDA label content (no label text provided).
Skyrizi is a biologic.
Not supported by the supplied FDA label content (no label text provided).
Skyrizi typically has market exclusivity that keeps competition limited for longer than small-molecule drugs.
Not supported by the supplied FDA label content (no label text provided).
As biosimilars enter, the average net price of Skyrizi can fall.
Not supported by the supplied FDA label content (no label text provided).
What a patient pays in Canada still depends on insurer/provincial negotiations.
Not supported by the supplied FDA label content (no label text provided).
Contradictions
Important Omissions
FDA label elements needed to evaluate safe and accurate prescribing (e.g., approved indication(s), dosage/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, and use in specific populations).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Claims focus on Canadian pricing/coverage/support rather than FDA labeling content; with no FDA label text provided, alignment and safety-critical labeling cannot be verified.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
No FDA-approved prescribing information was provided, so none of the extracted claims can be verified as supported by the FDA label.
Suggested Improvement
Provide the relevant FDA label sections/text (with citations) and ensure extracted claims map to on-label labeling topics (e.g., indications, dosing, contraindications, warnings/precautions, interactions, and specified populations).